Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CurveBeam AIASX:CVB +5.88% Debt-to-Equity is 0.47 as of Dec. 2025, which is 18% above its 10-year median of 0.40. The stock has 5 warning signs investors should review. Among 705 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 67.8% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CurveBeam AI's Debt-to-Equity or its related term are showing as below:
ASX:CVB'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.31 Med: 0.4 Max: 0.51
Current: 0.47
During the past 5 years, the highest Debt-to-Equity Ratio of CurveBeam AI was 0.51. The lowest was -0.31. And the median was 0.40.
ASX:CVB's Debt-to-Equity is ranked worse than 67.8% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ASX:CVB: 0.47
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
CurveBeam AI Debt-to-Equity Related Terms
CurveBeam AI Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for CurveBeam AI's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CVB vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, CurveBeam AI's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CurveBeam AI Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CurveBeam AI's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CurveBeam AI (ASX:CVB) has a Debt-to-Equity of 0.47 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CurveBeam AI and its competitors. This is 18% above median its historical median of 0.40. According to the industry distribution chart, CurveBeam AI ranks #478 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 67.8%.
Is CurveBeam AI's Debt-to-Equity too high?
CurveBeam AI's current Debt-to-Equity of 0.47 is 18% above median its 10-year median of 0.40. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. CurveBeam AI's value of 0.47 is 104.3% above this industry median. Based on the distribution chart, CurveBeam AI ranks #478 out of 705 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does CurveBeam AI's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #478 out of 705 companies for Debt-to-Equity. This places CurveBeam AI in the lower half of its industry. The industry median Debt-to-Equity is 0.23. CurveBeam AI's value of 0.47 is 104.3% above this benchmark. While the company's 10-year median is 0.40 vs. the industry median of 0.23, CurveBeam AI has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CurveBeam AI's current Debt-to-Equity of 0.47 is 104.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current Debt-to-Equity is 0.47, which is 18% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current Debt-to-Equity of 0.47. The current Debt-to-Equity is 0.47, which is 18% above median its 10-year median of 0.40 and 104.3% above the Medical Devices & Instruments industry median of 0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Debt-to-Equity is 0.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CVB has been successfully added to your 
